Galmed Pharmaceuticals (GLMD) EBIT Growth (1y) (2014 - 2024)
Galmed Pharmaceuticals (GLMD) EBIT Growth (1y) (2014 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.14% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 269.85% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,528.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -336.63% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -36.55% |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 13.96% |
| Jun 30, 2023 | 100.35% |
| Sep 30, 2022 | -110.97% |
| Sep 30, 2021 | -99.92% |
| Mar 31, 2021 | -95.22% |
| Dec 31, 2020 | -586.56% |
| Sep 30, 2020 | 86,112.87% |
| Jun 30, 2020 | -23.72% |
| Mar 31, 2020 | 59.95% |
| Dec 31, 2019 | 1,966.83% |
| Sep 30, 2019 | -61.34% |
| Jun 30, 2019 | -4,083.90% |
| Mar 31, 2019 | 57.87% |
| Dec 31, 2018 | 10.36% |
| Sep 30, 2018 | -56.74% |
| Jun 30, 2018 | -95.69% |
| Mar 31, 2018 | -21.60% |
| Dec 31, 2017 | -24.79% |
| Sep 30, 2017 | -25.52% |
| Jun 30, 2017 | -35.09% |